Market Place
Sourcing Support
Biogen Targets Patients Transitioning Off Lilly`s Kisunla
29 Apr 2026 //
BIOSPACE
Biogen inks $850M deal with TJ for China rights antibody
20 Apr 2026 //
FIERCE BIOTECH
Biogen Links Up With Alloy Platform To Boost ASO Drug Development
07 Apr 2026 //
FIERCE BIOTECH
Biogen`s Litifilimab Sparkles In Midphase Lupus Trial
30 Mar 2026 //
FIERCE BIOTECH
Biogen Announces Phase 2 Results for Litifilimab in Lupus in AAD
28 Mar 2026 //
GLOBENEWSWIRE
Alteogen Licenses Hybrozyme To Biogen For Subcutaneous Biologics
25 Mar 2026 //
PR NEWSWIRE
Long-Term LEQEMBI Treatment Persistence Data In Us Revealed
20 Mar 2026 //
PR NEWSWIRE
Long-Term LEQEMBI® Treatment Persistence Data In Us Revealed
20 Mar 2026 //
PR NEWSWIRE
Biogen To Unveil Late-Breaking Litifilimab Ph2 AMETHYST Data
19 Mar 2026 //
GLOBENEWSWIRE
Biogen Reports Salanersen Motor Gains in SMA After Gene Therapy
11 Mar 2026 //
GLOBENEWSWIRE
Biogen`s Alzheimer`s Tau Readout To Raise Further Inquiries
09 Feb 2026 //
BIOSPACE
Biogen`s `Bridge To Growth` Advances Stacked Phase 3 Pipeline
06 Feb 2026 //
BIOSPACE
Nature Medicine Releases Results Of Pivotal DEVOTE Study
04 Feb 2026 //
GLOBENEWSWIRE
Biogen’s Litifilimab Gains FDA Breakthrough Status for Lupus
28 Jan 2026 //
GLOBENEWSWIRE
Biogen Eyes Alzheimer`s Expansion Post-Leqembi Launch
14 Jan 2026 //
BIOSPACE
China Accepts BLA for Subcutaneous LEQEMBI in Early Alzheimer
05 Jan 2026 //
GLOBENEWSWIRE
Samsung Bioepis Launches Byooviz, Biosimilar for Lucentis in EU
02 Jan 2026 //
BUSINESSWIRE
Biogen, Stoke Enhance Epilepsy Drug`s Blockbuster Potential
08 Dec 2025 //
BIOSPACE
China Adds LEQEMBI to National Drug Reimbursement List
08 Dec 2025 //
GLOBENEWSWIRE
Eisai Reveals Extended Benefits Of LEQEMBI In Early Alzheimer
03 Dec 2025 //
GLOBENEWSWIRE
LEQEMBI Shows Neurotoxic A? Protofibril Impact In Alzheimer`s
02 Dec 2025 //
GLOBENEWSWIRE
Biogen, Stoke Announce Presentations at 2025 AES Annual Meeting
01 Dec 2025 //
GLOBENEWSWIRE
Eisai Files NDA for Subcutaneous LEQEMBI in Early AD in Japan
27 Nov 2025 //
GLOBENEWSWIRE
Eisai Files sBLA with FDA for LEQEMBI in Early Alzheimer Diseases
25 Nov 2025 //
PR NEWSWIRE
Biogen`s Leqembi Rises After Novo GLP-1 Fails In Alzheimer
24 Nov 2025 //
BIOSPACE
Versant Ventures Launches Biogen-Backed Dayra Therapeutics
24 Nov 2025 //
BUSINESSWIRE
Biogen Showcases Lecanemab Data At Alzheimer`s Disease Conference
20 Nov 2025 //
GLOBENEWSWIRE
Biogen Returns To Its Roots With A West Coast Immunology Outpost
18 Nov 2025 //
FIERCE BIOTECH
UK Approves Leqembi Iv for Early Alzheimer`s Disease
13 Nov 2025 //
GLOBENEWSWIRE
Biogen Ticks Up Sales Outlook Again As MS Franchise Holds Strong
30 Oct 2025 //
FIERCE PHARMA
Samsung Bioepis to Launch Byooviz in Europe in January 2026
29 Oct 2025 //
BUSINESSWIRE
Biogen Seeks To Stand Out In Lupus With New Anti-CD40L Data
28 Oct 2025 //
BIOSPACE
Health Canada Authorizes “LEQEMBI” For Early Alzheimer`s Disease
26 Oct 2025 //
GLOBENEWSWIRE
Biogen Licenses Vanqua Bio`s Immune Disorder Drug For $1.06B
25 Oct 2025 //
REUTERS
Biogen To Unveil More Phase 3 Dapirolizumab Pegol Data For Lupus
22 Oct 2025 //
GLOBENEWSWIRE
Leqembi Iqlik Autoinjector Honored in Time`s best Inventions List
14 Oct 2025 //
PR NEWSWIRE
Stoke Therapeutics, Biogen Unveil Zorevunersen Data at Meeting
09 Oct 2025 //
BUSINESSWIRE
Genentech Awarded $124M In Cabilly Patent Dispute With Biogen
06 Oct 2025 //
FIERCE PHARMA
Biogen Shuffles 20 Staff After Ending AAV Work
29 Sep 2025 //
BIOSPACE
China Approves `leqembi` Maintenance Dosing For Early Alzheimer
28 Sep 2025 //
GLOBENEWSWIRE
Biogen Discontinues All Aav Gene Therapy Work
26 Sep 2025 //
FIERCE BIOTECH
Lecanemab Approval For Alzheimer`s Treatment In Australia
24 Sep 2025 //
GLOBENEWSWIRE
FDA Rejects Biogen`s Higher Dose For Genetic Disorder Drug
24 Sep 2025 //
PRESS RELEASE
Biogen Inks $85 M Alcyone Buyout to Acquire Drug Delivery Tech
19 Sep 2025 //
FIERCE BIOTECH
Biogen Gets EU Approval for Zurzuvae for Postpartum Depression
17 Sep 2025 //
GLOBENEWSWIRE
Biogen`s `Underappreciated` Pipeline Revealed Through Lupus Study
09 Sep 2025 //
BIOSPACE
C4 Therapeutics highlight Biogen Collaboration Success
04 Sep 2025 //
GLOBENEWSWIRE
FDA Begins sBLA for Leqembi® Iqlik as Early Alzheimer`s Treatment
02 Sep 2025 //
PR NEWSWIRE
Eisai Begins Rolling sBLA for Leqembi Iqlik in Early Alzheimer
02 Sep 2025 //
GLOBENEWSWIRE
Eisai Scores FDA Nod for Subcutaneous Leqembi Maintenance Dose
29 Aug 2025 //
FIERCE PHARMA
Stoke, Biogen Present Zorevunersen Data In Dravet Syndrome
25 Aug 2025 //
PHARMAWEB
Biogen Boosts Sales Forecast as `New Biogen` Emerges
31 Jul 2025 //
FIERCE PHARMA
Biogen’s Leqembi Advances as CEO Eyes Pipeline Rebuild
31 Jul 2025 //
BIOSPACE
Biogen, Eisai’s Leqembi Slows Alzheimer’s Over 4-Year Treatment
31 Jul 2025 //
BIOSPACE
Four-Year LEQEMBI® Data Shows Benefit in Early Alzheimer’s
30 Jul 2025 //
PR NEWSWIRE
ZURZUVAE Gets CHMP Nod for Postpartum Depression
25 Jul 2025 //
GLOBENEWSWIRE
Biogen to Present Alzheimer’s Research at Conference
21 Jul 2025 //
GLOBENEWSWIRE
Lecanemab Drug Discovery Wins 9th Bioindustry Award in Japan
16 Jul 2025 //
PR NEWSWIRE
Stoke, Biogen Unveil Zorevunersen Data for Dravet Syndrome
10 Jul 2025 //
BUSINESSWIRE
Sage`s Search for Lifeline Ran Into Defiant Biogen CEO
03 Jul 2025 //
BIOSPACE
